{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-097802","form_type":"8-K","ticker":"NNVC","cik":"0001379006","company_name":"NANOVIRICIDES, INC.","filed_at":"2023-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.744831+00:00","generated_at":"2026-06-11T00:25:29.998899+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NanoViricides issues $1.5M convertible note to TheraCour in lieu of milestone payment","bullets":["Issued $1.5M convertible promissory note to TheraCour (related party) in lieu of $1.5M cash milestone payment under Licensing Agreement.","Note bears 12% annual interest, matures January 19, 2025; convertible into Series A Convertible Preferred Stock.","Dr. Anil Diwan (President/Chairman) owns ~90% of TheraCour; recused from board vote on agreement.","Note replaces milestone payment obligation for Initiation of Phase 1 Clinical Trials or Equivalent milestone.","Company retains customary representations and warranties; note is unregistered security."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-097802","json":"https://secwatch.observer/filing/0001104659-23-097802.json","markdown":"https://secwatch.observer/filing/0001104659-23-097802.md","text":"https://secwatch.observer/filing/0001104659-23-097802.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1379006/000110465923097802/0001104659-23-097802-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1379006/000110465923097802/tm2325384d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:25:29.998899+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20719e2676e1451cdda01c88a1da49923b1618be","claim":"NANOVIRICIDES, INC. incurred convertible notes of $1,500,000 with TheraCour Pharma, Inc. at twelve percent (12%) per annum maturing January 19, 2025.","evidence_excerpt":"by TheraCour within 3 months from Regulatory Approval. Upon achieving this milestone, the Registrant was obligated to pay TheraCour a cash milestone payment in the amount of $1,500,000. In lieu of this cash payment, TheraCour agreed to accept a Convertible Promissory Note in the principal amount of $1,500,000 effective July 19, 2023 (the “Note”). The","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465923097802/0001104659-23-097802-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$1,500,000"},{"label":"Counterparty","value":"TheraCour Pharma, Inc."},{"label":"Rate","value":"twelve percent (12%) per annum"},{"label":"Maturity","value":"January 19, 2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"260fe2c8acbdf82be61dd6586718fc955562c2af","claim":"NANOVIRICIDES, INC. entered into Deferred Expense Exchange Agreement with TheraCour Pharma, Inc. valued at $1,500,000 Convertible Promissory Note; interest rate 12% per annum; due 2025-01-19 (effective 2023-07-19).","evidence_excerpt":"On August 29, 2023, NanoViricides, Inc. (the “Registrant”) entered into a Deferred Expense Exchange Agreement (the “Agreement”) with TheraCour Pharma, Inc., a Connecticut corporation (“TheraCour”) effective as of July 19, 2023.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465923097802/0001104659-23-097802-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"TheraCour Pharma, Inc."},{"label":"Value","value":"$1,500,000 Convertible Promissory Note; interest rate 12% per annum; due 2025-01-19"},{"label":"Effective","value":"2023-07-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}